Complementary, Not Competing: How an Endocrinologist Compares Dual Incretin Approaches for Obesity and MASH

This episode, titled 'Complementary, Not Competing: How an Endocrinologist Compares Dual Incretin Approaches for Obesity and MASH,' features Jaime Almandoz, MD discussing the following critical questions:

Please explain what a dual GLP-1/glucagon receptor agonist adds mechanistically compared to a GLP-1 receptor agonist alone.

How does this dual GLP-1/glucagon mechanism compare to GIP/GLP-1 co-agonism, and are there metabolic patient profiles where one approach might be preferable over the other?

Almandoz explained that while GLP-1 receptor agonism alone delivers meaningful benefits in appetite regulation, satiety, glycemic control, and cardiorenal and liver outcomes, the addition of glucagon receptor agonism introduces a distinct and complementary layer of biology that goes beyond weight loss alone to address the metabolic drivers most closely linked to insulin resistance, cardiometabolic risk, and MASH progression. He also offered a nuanced comparison of GLP-1/glucagon co-agonism and GIP/GLP-1 co-agonism, framing them as complementary rather than competing strategies, noting that GIP/GLP-1 co-agonism has demonstrated impressive effects on body weight, glycemic control, and ectopic fat reduction, while GLP-1/glucagon co-agonism introduces a different biological strategy that is compelling given the expression of glucagon receptors in the liver and the potential for meaningful hepatic metabolic effects that differentiate it in the MASH space.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'SYNCHRONIZE-1 Through an Endocrinologist's Lens: Weight Loss Quality, Visceral Fat, and Liver Fat Reduction,' features Jaime Almandoz advancing his conversation on obesity and MASH and focusing on how he interprets the SYNCHRONIZE-1 findings.